These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25120190)

  • 1. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
    Barszczyk M; Buczkowicz P; Castelo-Branco P; Mack SC; Ramaswamy V; Mangerel J; Agnihotri S; Remke M; Golbourn B; Pajovic S; Elizabeth C; Yu M; Luu B; Morrison A; Adamski J; Nethery-Brokx K; Li XN; Van Meter T; Dirks PB; Rutka JT; Taylor MD; Tabori U; Hawkins C
    Acta Neuropathol; 2014 Dec; 128(6):863-77. PubMed ID: 25120190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
    Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
    Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
    Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
    Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
    Hu Y; Bobb D; He J; Hill DA; Dome JS
    Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.
    Marian CO; Cho SK; McEllin BM; Maher EA; Hatanpaa KJ; Madden CJ; Mickey BE; Wright WE; Shay JW; Bachoo RM
    Clin Cancer Res; 2010 Jan; 16(1):154-63. PubMed ID: 20048334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition.
    Castelo-Branco P; Zhang C; Lipman T; Fujitani M; Hansford L; Clarke I; Harley CB; Tressler R; Malkin D; Walker E; Kaplan DR; Dirks P; Tabori U
    Clin Cancer Res; 2011 Jan; 17(1):111-21. PubMed ID: 21208905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of telomerase inhibition on prostate tumor-initiating cells.
    Marian CO; Wright WE; Shay JW
    Int J Cancer; 2010 Jul; 127(2):321-31. PubMed ID: 19908230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
    Hu Y; Bobb D; Lu Y; He J; Dome JS
    Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
    Salloum R; Hummel TR; Kumar SS; Dorris K; Li S; Lin T; Daryani VM; Stewart CF; Miles L; Poussaint TY; Stevenson C; Goldman S; Dhall G; Packer R; Fisher P; Pollack IF; Fouladi M; Boyett J; Drissi R
    J Neurooncol; 2016 Sep; 129(3):443-451. PubMed ID: 27350411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase inhibition as a novel therapy for pediatric ependymoma.
    Wong VC; Morrison A; Tabori U; Hawkins CE
    Brain Pathol; 2010 Jul; 20(4):780-6. PubMed ID: 20184588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma.
    Ferrandon S; Malleval C; El Hamdani B; Battiston-Montagne P; Bolbos R; Langlois JB; Manas P; Gryaznov SM; Alphonse G; Honnorat J; Rodriguez-Lafrasse C; Poncet D
    Mol Cancer; 2015 Jul; 14():134. PubMed ID: 26183089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
    Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
    Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth.
    Lu R; Pal J; Buon L; Nanjappa P; Shi J; Fulciniti M; Tai YT; Guo L; Yu M; Gryaznov S; Munshi NC; Shammas MA
    Oncogene; 2014 Mar; 33(12):1495-505. PubMed ID: 23604115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT Promoter Mutations but not the Alternative Lengthening of Telomeres Phenotype Are Present in a Subset of Ependymomas and Are Associated With Adult Onset and Progression to Ependymosarcoma.
    Brügger F; Dettmer MS; Neuenschwander M; Perren A; Marinoni I; Hewer E
    J Neuropathol Exp Neurol; 2017 Jan; 76(1):61-66. PubMed ID: 28040793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomere biology of pediatric cancer.
    Tabori U; Dome JS
    Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.
    Ridley L; Rahman R; Brundler MA; Ellison D; Lowe J; Robson K; Prebble E; Luckett I; Gilbertson RJ; Parkes S; Rand V; Coyle B; Grundy RG;
    Neuro Oncol; 2008 Oct; 10(5):675-89. PubMed ID: 18701711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms.
    Brennan SK; Wang Q; Tressler R; Harley C; Go N; Bassett E; Huff CA; Jones RJ; Matsui W
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
    Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
    Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo.
    Yu L; Baxter PA; Voicu H; Gurusiddappa S; Zhao Y; Adesina A; Man TK; Shu Q; Zhang YJ; Zhao XM; Su JM; Perlaky L; Dauser R; Chintagumpala M; Lau CC; Blaney SM; Rao PH; Leung HC; Li XN
    Neuro Oncol; 2010 Jun; 12(6):580-94. PubMed ID: 20511191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.